Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip LlcfiledCriticalTheravance Biopharma R&D Ip Llc
Publication of HK1161220ApublicationCriticalpatent/HK1161220A/en
The invention provides crystalline solid forms of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamino)-2-cyclohexylmethyl-butyric acid. The invention also provides pharmaceutical compositions comprising such crystalline solid forms, methods of using such crystalline solid forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline solid forms.
HK12101550.6A2008-12-102009-12-09Crystalline forms of a 3-carboxypropyl-aminotetralin compound
HK1161220A
(en)